Acute respiratory distress syndrome. Adult respiratory distress syndrome
Conditions
Interventions
Intervention 1: intervention group 1: these patients will be administered with 4 mg of intravenous selenase (produced by Biosyn company, Germany). Then, for 3 days the will receive 1mg/12h then for th
Treatment - Drugs
Placebo
intervention group 1: these patients will be administered with 4 mg of intravenous selenase (produced by Biosyn company, Germany). Then, for 3 days the will receive 1mg/12h then for the last 10 days t
Control group 1: they will receive placebo with the exact same doses.
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Major inclusion criteria: patients above 18 years; asymmetric and diffused involvemnet of lungs in chest X-ray; lung involvement less than a week; proportion of arterial oxygen pressure (Pao2) to Fio2 more than 200; Exclusion criteria: hypersensitivity to Selenium; pregnancy and lactation; renal failure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxidative stress status(gluthatione peroxidase). Timepoint: One day before the intervention. Seven days after intervention. Fourteen days after the intervention. Method of measurement: using FRAP and TRAP kits.;Ventilation free days. Timepoint: number of days that patients do not require mechanical ventilation, within the 14 days of study period. Method of measurement: with counting the ventilation free days and recording them in forms. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vasopressor free days. Timepoint: number of days that patients do not require vasopressor administration, within the 14 days of study period. Method of measurement: with counting vasopressor free days and recording them in forms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Zohreh Ostadi
Tabriz University of Medical Sciences
Outcome results
None listed